R3® Acetabular System in Patients With Degenerative Hip Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a prospective, non-randomized, consecutive series, multicenter clinical study that will include patients who will have total hip replacement with the R3 Acetabular System.
| Condition |
|---|
|
Osteoarthritis |
| Study Type: | Observational |
| Study Design: | Time Perspective: Prospective |
| Official Title: | A Prospective, Multicenter, Non-randomized, Clinical Outcomes Study of the R3® Acetabular System in Patients With Degenerative Hip Disease |
- Effectiveness will be measured using the Harris Hip Score (HHS), The HOOS self assessment questionnaire, and radiographic assessment. Radiographic measures consist of radiolucencies, component position changes, and bony changes. [ Time Frame: 3 months, 1-5 years ] [ Designated as safety issue: Yes ]The objective of this study is to establish the safety and effectiveness of the R3 Acetabular System in primary total hip replacement.
- Adverse Events [ Time Frame: Post Operative - 5 years ] [ Designated as safety issue: Yes ]All perioperative and postoperative device-related and surgical adverse events will be recorded during this study.
| Estimated Enrollment: | 158 |
| Study Start Date: | October 2009 |
| Estimated Study Completion Date: | December 2014 |
| Estimated Primary Completion Date: | October 2014 (Final data collection date for primary outcome measure) |
The study design was selected to assess the safety and effectiveness profile of the R3 Acetabular System in patients with degenerative joint disease requiring primary total hip replacement. A non¬-randomized, consecutive series of up to 158 patients will be enrolled, and a maximum of 8 sites will participate in the study. Each site is allowed to enroll up to 22 patients. When 158 patients are enrolled from all sites, enrollment will be stopped, regardless of the number contributed from each site. The clinical data from this study will be compared with a historical control. The study will include follow up through 5 years.
Eligibility| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
This clinical study can fulfill its objectives only if appropriate subjects are enrolled. All relevant medical and non-medical conditions should be taken into consideration when deciding whether a particular patient is suitable.
Inclusion Criteria:
- Patient is of legal age to consent and skeletally mature.
- Patient requires primary total hip arthroplasty due to non-inflammatory degenerative joint disease (e.g. osteoarthritis, traumatic arthritis, avascular necrosis, and dysplasia/DDH)
- Patient has met an acceptable preoperative medical clearance and is free from or treated for cardiac, pulmonary, hematological, etc., conditions that would pose excessive operative risk.
- The patient will be available for follow-up throughout the duration of the study.
Exclusion Criteria:
- Patient has active infection or sepsis (treated or untreated)
- Patient has any vascular insufficiency, muscular atrophy, or neuromuscular disease severe enough to compromise implant stability or postoperative recovery.
- Patient is pregnant or plans to become pregnant during the course of the study Patient has inadequate bone stock to support the device (e.g. severe osteopenia, family history of severe osteoporosis or osteopenia)
- Patient has inflammatory joint disease (e.g. rheumatoid arthritis)
- Patient has known moderate to severe renal insufficiency.
- Patient has a known or suspected metal sensitivity.
- Patient is immunosuppressed or receiving high doses of corticosteroids.
- Patient has an emotional or neurological condition that would pre-empt their ability or willingness to participate in the study including mental illness, mental retardation, or drug, alcohol abuse.
- Patient has BMI >40.
- Patient is a prisoner
Contacts and Locations| United States, Florida | |
| Richard Steinfeld | |
| Vero Beach, Florida, United States, 32960 | |
| Principal Investigator: | Richard McCalden, MD | London Health Science Centre-University Hospital London Ontario |
| Principal Investigator: | Colin Burnell, MD | Concordia Hospital, Winnipeg, Canada |
| Principal Investigator: | James Comadoll, MD | Ro Medical Orthopedics, Salisbury NC |
| Principal Investigator: | Richard Steinfeld, MD | Orthopaedic Center of Vero Beach, Vero Beach, FL |
| Principal Investigator: | Craig Della Valle, MD | Rush University Medical Center |
| Principal Investigator: | John Masonis, MD | OrthoCarolina Research Institute |
| Principal Investigator: | Ryan Nunley, MD | Washington University Orthopedics |
| Principal Investigator: | Michael Dunbar, MD | Halifax Infirmary |
More Information
No publications provided
| Responsible Party: | Smith & Nephew, Inc. |
| ClinicalTrials.gov Identifier: | NCT01407029 History of Changes |
| Other Study ID Numbers: | R3H01 |
| Study First Received: | August 6, 2010 |
| Last Updated: | September 16, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
ClinicalTrials.gov processed this record on June 18, 2013